Sun11232014

Last update 09:34:07 AM EST

Gilead Pays $125 Million for Knight's Priority Review Voucher

Gilead Pays $125 Million for Knight's Priority Review Voucher


Gilead Sciences is paying Canadian pharmaceutical ...

Agios Presents Promising Early Results for its Blood Cancer Candidate

Agios Presents Promising Early Results for its Blood Cancer Candidate

Agios Pharmaceuticals’ investigational compound ...

European Regulators Approve Gilead's Harvoni for Hepatitis C Patients

European Regulators Approve Gilead's Harvoni for Hepatitis C Patients

Gilead Sciences, Inc. recently announced that it...

Daniel J. Klein Joins PAN Foundation as the New President & CEO

Daniel J. Klein Joins PAN Foundation as the New President & CEO

Today, the Patient Access Network (PAN) Foundati...

Allergan Agrees to $66 Billion Takeover Bid from Actavis

Allergan Agrees to $66 Billion Takeover Bid from Actavis

Today, Irish pharmaceutical company Actavis pl...

AbbVie's Hep C Regimen Recommended for Approval by European Regulators

AbbVie's Hep C Regimen Recommended for Approval by European Regulators

Today, AbbVie announced that European health regulators granted a positive o...

European Regulators Approve Gilead's Harvoni for Hepatitis C Patients

European Regulators Approve Gilead's Harvoni for Hepatitis C Patients

Gilead Sciences, Inc. recently announced that its hepatitis C drug has been ap...

CHMP Recommends Approval of Novartis' Psoriasis Drug

CHMP Recommends Approval of Novartis' Psoriasis Drug

Novartis AG announced that it has won backing from European regulators for its...

FDA Approves Genzyme's Multiple Sclerosis Drug Lemtrada

FDA Approves Genzyme's Multiple Sclerosis Drug Lemtrada

The US Food and Drug Administration (FDA) recently reversed its earlier deci...

IMS Study Forecasts Global Drug Spending to Increase 30% by 2018

IMS Study Forecasts Global Drug Spending to Increase 30% by 2018

Global spending on medicines is expected to soar by as much as 30 percent from...

Gilead Pays $125 Million for Knight's Priority Review Voucher

Gilead Pays $125 Million for Knight's Priority Review Voucher


Gilead Sciences is paying Canadian pharmaceutical company Knight Therapeutics $1...

Daniel J. Klein Joins PAN Foundation as the New President & CEO

Daniel J. Klein Joins PAN Foundation as the New President & CEO

Today, the Patient Access Network (PAN) Foundation announced that Daniel J. Kl...

Allergan Agrees to $66 Billion Takeover Bid from Actavis

Allergan Agrees to $66 Billion Takeover Bid from Actavis

Today, Irish pharmaceutical company Actavis plc announced that it will acqui...

FDA Grants Fast Track Designation to Merrimack's Pancreatic Cancer Drug

FDA Grants Fast Track Designation to Merrimack's Pancreatic Cancer Drug

The US Food and Drug Administration (FDA) has granted Fast Track designation...

Study Finds the Combination of Two Existing Cancer Drugs Benefit Advanced Kidney Cancer Patients

Study Finds the Combination of Two Existing Cancer Drugs Benefit Advanced Kidney Cancer Patients

Researchers found that patients with a type of advanced kidney cancer respon...

CytRx's Cancer Drug Program Placed on Partial Clinical Hold by the FDA

CytRx's Cancer Drug Program Placed on Partial Clinical Hold by the FDA

The US Food and Drug Administration (FDA) has placed a partial clinical hold o...

Agios Presents Promising Early Results for its Blood Cancer Candidate

Agios Presents Promising Early Results for its Blood Cancer Candidate

Agios Pharmaceuticals’ investigational compound demonstrated positive early re...

Bristol-Myers Squibb's Opdivo Demonstrates Promising Late-Stage Results in Patients with Advanced Melanoma

Bristol-Myers Squibb's Opdivo Demonstrates Promising Late-Stage Results in Patients with Advanced Melanoma

A Bristol-Myers Squibb (BMS) drug held skin cancer patients live longer than...

Genentech's Avastin Receives FDA-Approval for Treatment of Ovarian Cancer

Genentech's Avastin Receives FDA-Approval for Treatment of Ovarian Cancer

On Friday, Genentech, a member of the Roche Group, announced that the US Foo...

Pfizer Enters $2.85 Billion Cancer Deal with Merck

Pfizer Enters $2.85 Billion Cancer Deal with Merck

Pfizer Inc. has agreed to pay Merck KGaA $850 million upfront and as much as...